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Abstract
Background: A high level of soluble thrombomodulin (sTM) is associated with a lower risk of thrombosis but can cause 
severe bleeding after operations. Deep vein thrombosis (DVT) and blood loss are serious threats after orthopedic surgery. The aim 
of our pilot study was to evaluate the effect of the preoperative level of sTM on coagulation and inflammation as well as the blood 
loss and the development of symptomatic DVT after total large joint replacement.
Methods and Results: In all patients (n=50) who underwent total hip or knee replacement, sTM, PrC, D-dimer, vWF, CRP, 
and platelets were determined before and after the operation. According to the preoperative sTM level, patients were divided into 
2 groups: the thrombomodulin low (TML) group (n=25) and thrombomodulin high (TMH) group (n=25). The concentration of 
sTM was 4.4 [3.4, 4.7] ng/ml in the TML-group and 8.7[7.3, 10.6] ng/ml in the TMH-group. After surgery, D-dimer, vWF, platelet 
count and CRP were higher and total blood loss was lower in the TML group. In the TML-group, a symptomatic DVT was detected 
in 3(12%) patients; in the TMH-group, a symptomatic DVT was identified only in 1(4%) case.
Conclusion: These findings support the important role of sTM in coagulation, inflammation, bleeding, and presumably in 
venous thrombosis after major orthopedic surgery. (Int J Biomed. 2016;6(3):213-217.).
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Abbreviations
CRP, C-reactive protein; DVT, deep vein thrombosis; IQR, interquartile range; PrC, protein C; TM, thrombomodulin; sTM, 
soluble TM; vWF, von Willebrand factor.
Introduction
Human TM is a single-chain, type 1 transmembrane 
glycoprotein mainly expressed on the luminal surface of the 
vascular endothelium.[1] TM binds thrombin and modifies its 
conformation, which allows activation of PrC.[2] In addition, 
TM plays an important role in mediating anti-inflammatory 
activity.[3]   Plasma sTM is formed by proteolysis of membrane-
bound TM[4] with anticoagulant and anti-inflammatory pro-
perties.[5] Experimental and clinical studies have shown that 
a low level of sTM is associated with a prethrombotic state 
and venous thrombosis.[6-9] Application of recombinant human 
sTM is effective in prevention of the venous thrombosis in a 
rat model and after total hip replacement [10,11] for the treatment 
of disseminated intravenous coagulation.[12]  On the other 
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hand, the increased level of sTM causes severe bleeding after 
injuries and operations. [13]
Thromboembolic complications and increased blood 
loss are serious threats after major orthopedic surgery.[14] The 
incidence of venography-detected DVT ranges from 42% to 
57% in total hip replacement and 41% to 85% in total knee 
replacement, in the absence of prophylaxis. [15]  
The aim of our pilot study was to evaluate the effect of 
the preoperative level of sTM on coagulation and inflammation 
as well as the blood loss and the development of symptomatic 
DVT after total large joint replacement.
Materials and Methods
The study included 50 patients (22 men, aged from 
30 to 74 years) admitted for total hip or knee replacement. 
Exclusion criteria were coagulopathy and anticoagulant or 
antiplatelet therapy before surgery. The study was conducted 
in accordance with ethical principles of the Declaration 
of Helsinki and approved by the local Ethics Committees. 
Written informed consent was obtained from each patient.
All patients received antithrombotic prophylaxis with 
enoxaparin (40 mg daily), first administered in the evening 
before the operation, and then administered daily for two 
weeks. In order to limit blood loss, all patients included in the 
study received tranexamic acid (15-20 mg/kg intravenously). 
The first dose was administered 20-30 minutes before the 
surgical incision and the second dose was administered 6 
hours after the first infusion. Intraoperative and postoperative 
bleeding was monitored. Clinical parameters indicative of 
thrombosis were recorded, and patients with suspected DVT 
were admitted for Doppler ultrasound verification. 
All patients were divided into 2 groups according to the 
preoperative sTM level (Fig.1). The median value for sTM 
was 5.6 ng/mL. The data obtained from patients with sTM 
level below the median was combined into a thrombomodulin 
low (TML) group (n=25); the data obtained from patients 
with sTM levels equal to or above the median made up the 
thrombomodulin high (TMH) group (n=25). The concentration 
of sTM was 4.4 [3.4, 4.7] ng/ml in the TML-group and 8.7[7.3, 
10.6] ng/ml in the TMH-group. The normal reference range 
was 5.1[2.9, 7.6] ng/ml, according to the manufacturer of the 
reagents. Characteristics of patients and surgical procedures in 
selected groups are presented in Table 1.  The age of patients 
in the TMH-group was higher than in the TML-group, and 
this fact was taken into account when carrying out a statistical 
analysis of research results.
Blood sampling was performed at set time (T) points 
during the perioperative period: preoperatively 1 to 2 days 
(T1), 30 minutes after completing the replacement (T2), 
postoperative Day 1 (T3), Day 3 (T4), Day 7 (T5), and Day 
14 (T6). Venous blood samples were collected in the morning 
into a test tube containing a 3.2% sodium citrate solution 
in a ratio of 1:9 sodium citrate/blood. Platelet count was 
determined in EDTA-stabilized blood. Blood serum was used 
for quantitative determination of C-reactive protein. 
The following analyses were carried out for all patients: 
TM («Human sCD141 ELISA Kit», Gen Probe Diaclone, 
France); PrC («Technozym Protein C ELISA», Technoclone, 
Austria); D-dimer («Technozym D-dimer ELISA», 
Technoclone, Austria); von Willebrand factor («Technozym 
vWF: Ag ELISA», Technoclone, Austria), platelet count. 
C-reactive protein («High Sensitivity C-Reactive Protein 
Enzyme Immunoassay Kit», Biomerica, Germany) was 
determined for 38 patients. All analyses were performed in 
accordance with the manufacturer›s instructions. 
Fig 1. Coagulation and inflammation parameters before 
and after total large joints replacement. 
Differences in concentrations and activity of sTM (A), PrC 
(B), D dimer (C), platelet count (D), vWF (E), CRP (F) for 
TML and TMH groups are shown in histogram (*-P<0.05; 
**-P<0.01; ***-P<0.001). P1 - statistical significance of 
postoperative changes for the TML-group; P2 - statistical 
significance of postoperative changes for the TMH-group.  
Table 1. 
Baseline characteristics of patients and surgical aspects
Variable TML group TMH group P
Gender (male/female), No (%) 10/15 (40/60) 12/13 (48/52) 0.573
Age, years, median [IQR] 51 [47, 63] 62 [57, 65] 0.032
Type of surgery 
(THR/TKR), No. (%) 21/4 (84/16) 20/5 (80/20) 0.818
Prostheses 
(cementless/cemented), No.(%) 19/6 (76/24) 15/10 (60/40) 0.335
Duration of surgery,
min, median [IQR] 100 [85,110] 100 [90,120] 0.397
Type of anesthesia 
(total/regional ), No.(%) 10/15 (40/60) 6/19 (24/76) 0.335
    THR - total hip replacement, TKR – total knee replacement. The  
results are expressed as a Number (percentage) and Median [IQR]. 
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Statistical differences between two groups were analyzed 
by nonparametric Mann Whitney U test; the differences 
between time points T1 – T6 - by Friedman’s ANOVA 
by ranks. A probability value of P<0.05 was considered 
statistically significant. The effect of age was analyzed by 
regression analysis and analysis of covariance. The results are 
expressed as Median [interquartile range (IQR)].
Results and Discussion
We observed that the patients with higher levels of sTM 
were older. A similar association between sTM and age was 
found earlier.[16]  Blood sTM level is determined by hereditary 
factors [9,13] and by pathological changes that lead to increased 
proteolytic cleavage of endothelial TM.[17] TM expression is 
depressed in the aged.[18] On the other hand, aging is often 
accompanied by increasing endothelial dysfunction;[19]  it can 
enhance the shedding of the soluble fragments of TM into 
circulating blood. Regression analysis showed that in the 
TMH-group, the patients’ age affects only the preoperative 
level of PrC and CRP, as well as the platelet count at day 7 
after the operation. After analysis of covariance, results for the 
dependent parameters were adjusted. 
sTM level in the TML-group increased by Day 1 after 
surgery and stayed above the initial level until Day 14. On 
the contrary, in the TMH-group, TM level decreased after 
the operation and then was gradually restored (P<0.02 and 
P<0.001 respectively in Friedman’s ANOVA, Fig. 1A). 
Despite the decline in the level of sTM in the TMH-group, 
significant differences in sTM levels between the groups 
were observed throughout the study period, and we can 
conclude that the postoperative level of sTM depends on its 
preoperative level. 
PrC levels in both groups significantly decreased 
after the operation, and then gradually recovered (P<0.001 
in Friedman’s ANOVA for both; Fig. 1B). We observed a 
tendency to a lower level of PrC in the TMH-group compared 
with the TML-group throughout the study period. The observed 
differences were statistically significant by Day 7 (P=0.034). 
We cannot exclude that when there is a decrease in the liver 
production of PrC, an increase of the TM cleavage may have a 
compensatory effect for the anticoagulant pathways. 
The concentration of D-dimer in TML-group was 
greatly increased immediately after surgery and Day 1 after 
the joint replacement. We observed a significant shift towards 
normalization in the concentration of D-dimer by postoperative 
Day 3, which was followed by another increase in  the D-dimer 
level (P<0.001 in Friedman’s ANOVA for both; Fig. 1C). 
The TMH-group had a more rapid decrease in the activity of 
coagulation after the operation. The concentration of D-dimer 
was substantially lower in this group than in the TML-group 
by Day 1 after surgery (P=0.002). Soluble TM fragments 
have full cofactor activity and the ability to bind thrombin 
and activate PrC.[1] A more rapid decrease of the D-dimer 
level is apparently due to more effective inactivation of the 
thrombin in patients with high levels of TM. We can assume 
that higher levels of sTM provide a more effective inhibition 
of coagulation induced by total large joint replacement.
The platelet count performed before surgery in the TMH-
group was significantly lower than in the TML-group. After a 
total large joint replacement in both groups, the platelet count 
decreased for 3 days followed by a gradual increase exceeding 
the preoperative level (P<0.001 in Friedman’s ANOVA for 
both; Fig. 1D). Significant differences between the groups 
remained in the postoperative period. A negative relationship 
between platelet count and sTM level was found in both 
healthy persons and those with pathological conditions.[16,20] 
We observed a similar relationship in our study before and 
after major orthopedic surgery. 
vWF is considered to be one of the known endothelial 
markers, and changes in its concentration reflect the degree of 
the inflammatory response after large joint replacement.[21]   We 
observed a gradual increase in vWF over time in both groups 
(P<0.001 in Friedman’s ANOVA for both; Fig. 1E). However, 
the increase in vWF was less prominent in the TMH-group 
than in the TML-group, and these differences reached 
statistical significance by Day 7 (P=0.032).
The serum level of CRP is an indicator of the acute 
phase inflammatory response and can be used as a monitoring 
tool.[22]  The concentration of CRP was significantly increased 
after surgery, reaching maximum values by Day 3. After that, 
the CRP level had a tendency to normalize but was never able 
to reach the baseline during the study period (P<0.001 in 
Friedman’s ANOVA for both; Fig. 1F). CRP dynamics showed 
a similar character in both groups; however, the maximum CRP 
level was significantly lower in the TMH-group than in the 
TML-group (P=0.019). TM has been shown to mediate anti-
inflammatory activities using activated protein C-dependent 
and activated protein C-independent mechanisms.[3] In our 
study, a higher level of sTM was associated with less increase 
of CRP and vWF after surgery. We concluded that sTM 
reduces the intensity of the inflammatory response after a total 
large joint replacement.
Intraoperative and postoperative bleeding monitoring 
has shown that the total blood loss (Intraoperative and 
postoperative within 24 hours) was significantly higher in the 
TMH-group than in the TML-group (Fig.2). 
Fig. 2. Total bleeding (ml) after a total large 
joint replacement. 
The box represents the median and IQR, 
the whiskers represents the minimum and 
maximum, P=0.026.
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There were no significant differences in the localization 
of the operated segment, the duration of surgery, and the type 
of anesthesia between groups with high and low levels of sTM 
(Table 1). However, the blood loss was significantly greater 
in patients with higher sTM levels. Apparently, a high sTM 
level promotes rapid activation of PrC and early interruption 
of thrombin generation. This worsens the propagation phase 
of coagulation and increases blood loss. Our results are in line 
with the observation of Y. Dargaud et al. (2015); they have 
shown that increased levels of sTM cause severe bleeding 
after injuries and operations.[13] 
Platelets play a critical role in hemostasis during vessel 
damage. In our study, the high sTM level was associated with 
a relatively low platelet count in the perioperative period, 
which suggests that a synergy of these factors contributes to 
the blood loss.
Previous experimental studies suggest that TM deficiency 
is associated with the prethrombotic state.[6,7] Significantly 
lower levels of plasma sTM were detected in patients with 
thrombosis in comparison with healthy individuals.[8] We 
have detected less venous thrombosis after total large joint 
replacement in patients who have a higher sTM level before 
and after surgery. In the TML-group, a symptomatic DVT was 
detected in 3(12%) patients; in the TMH-group, a symptomatic 
DVT was identified only in 1(4%) case. Although the 
differences did not reach statistical significance, our results do 
not contradict previously published data.
Our study has some limitations: a relatively small 
number of patients; participants were divided into groups 
retrospectively according to the median of the preoperative 
sTM level; connection of sTM with age; Doppler ultrasound 
was used only for confirming a symptomatic DVT, so we could 
not detect a “silent” thrombosis. Despite these limitations, we 
assume the obtained results support a link between the variation 
in preoperative sTM level and the activity of coagulation 
and inflammation after total large joint replacement. Further 
research may help in preoperative preparation and post-
operative treatment of patients who require major orthopedic 
surgery.
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